February 2017:

An Evidence-Based Approach to IBS and CIC: Applying New Advances to Daily Practice

Gastroenterology & Hepatology February 2017, Volume 13, Issue 2, Supplement 1 A Review of an Adjunct Clinical Symposium of the American College of Gastroenterology Meeting October […]

December 2016:

Highlights in the Treatment of Hepatitis C Virus From the 2016 AASLD Liver Meeting

Gastroenterology & Hepatology December 2016, Volume 12, Issue 12, Supplement 6 A Review of Selected Presentations From the 2016 AASLD Liver Meeting • November 11-15, 2016 […]

,

A Step-by-Step Approach to the Diagnosis and Management of Hepatic Encephalopathy in the United States, and Primary Biliary Cholangitis: Diagnosis and Management

Gastroenterology & Hepatology December 2016, Volume 12, Issue 12, Supplement 5   A Step-by-Step Approach to the Diagnosis and Management of Hepatic Encephalopathy in the United […]

October 2016:

The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations

Ira M. Jacobson, MD

Gastroenterology & Hepatology October 2016, Volume 12, Issue 10, Supplement 4 Ira M. Jacobson, MD Chair, Department of Medicine Icahn School of Medicine at Mount Sinai […]

September 2016:

The Gastro & Hep Report Fall 2016

Gastroenterology & Hepatology The Gastro & Hep Report A Special Meeting Review Edition Fall 2016 Comprehensive Reports on the Latest Advances in Gastroenterology and Hepatology From: […]

August 2016:

Advances in IBS 2016: A Review of Current and Emerging Data

Gastroenterology & Hepatology August 2016, Volume 12, Issue 8, Supplement 3 Philip S. Schoenfeld, MD, MSEd, MSc Professor of Medicine Director of the GI Epidemiology Training […]

June 2016:

Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting

Gastroenterology & Hepatology Volume 12, Issue 6, Supplement 2 June 2016 Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting The […]

February 2016:

CCFA/Advances in Inflammatory Bowel Diseases 2015: Highlights in Ulcerative Colitis and Crohn’s Disease

Volume 12, Issue 2, Supplement 1 February 2016 CCFA/Advances in Inflammatory Bowel Diseases 2015: Highlights in Ulcerative Colitis and Crohn’s Disease A Review of Selected Presentations […]

November 2015:

Serologic Monitoring and Testing in IBD: Highlights From the 2015 DDW and Best Use in Clinical Practice

Volume 11, Issue 11, Supplement 4 November 2015 Serologic Monitoring and Testing in IBD: Highlights From the 2015 DDW and Best Use in Clinical Practice Digestive […]

September 2015:

The Gastro & Hep Report

Comprehensive Reports on the Latest Advances in Gastroenterology and Hepatology From: • The 50th Annual Meeting of the European Association for the Study of the Liver April […]

June 2015:

Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015

Volume 11, Issue 6, Supplement 3  June 2015 Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015 The 50th Annual Meeting of the […]

April 2015:

The Gastro & Hep Report

Gastroenterology & Hepatology Spring 2015   Comprehensive Reports on the Latest Advances in Gastroenterology & Hepatology From: American College of Gastroenterology 2014 Annual Scientific Meeting October […]

New and Emerging Treatment Options for Irritable Bowel Syndrome

Gastroenterology & Hepatology April 2015, Volume 11, Issue 4, Supplement 2   Moderator Brian E. Lacy, PhD, MD Professor of Medicine, Geisel School of Medicine at Dartmouth, Chief […]

March 2015:

Emerging Treatment Options in Mild to Moderate Ulcerative Colitis

Gastroenterology & Hepatology March 2015, Volume 11, Issue 3, Supplement 1   Moderator Gary R. Lichtenstein, MD Professor of Medicine, Director, Center for Inflammatory Bowel Disease, University of […]

December 2014:

New Diagnostic Strategies for Detection of Helicobacter pylori Infection in Pediatric Patients

Gastroenterology & Hepatology December 2014, Volume 10, Issue 12, Supplement 7   Moderator Benjamin D. Gold, MD GI Care for Kids, LLC, Children’s Center for Digestive Healthcare […]

Highlights in the Treatment of Hepatitis C Virus From the 2014 Liver Meeting

Gastroenterology & Hepatology December 2014, Volume 10, Issue 12, Supplement 6   A Review of Selected Presentations From the 2014 Liver Meeting November 7-11, 2014 • […]

October 2014:

The Gastro & Hep Report Fall 2014

Gastroenterology & Hepatology Fall 2014   A Special Meeting Review Edition Comprehensive Reports on The Latest Advances In Gastroenterology & Hepatology From: Digestive Disease Week May […]

July 2014:

Advances in Hepatic Encephalopathy From EASL 2014

Steven L. Flamm, MD

Volume 10, Issue 7, Supplement 5 Advances in Hepatic Encephalopathy From EASL 2014 A Review of Selected Presentations From the 49th Annual Meeting of the European […]

Highlights in Anti-Tumor Necrosis Factor Monitoring and Antibody Monitoring From the 2014 DDW Meeting

July 2014, Volume 10, Issue 7, Supplement 4 Highlights in Anti-Tumor Necrosis Factor Monitoring and Antibody Monitoring From the 2014 DDW Meeting Digestive Disease Week 2014 May […]

Clinical Roundtable Monograph: Clinical Rationale for Confirmation Testing After Treatment of Helicobacter pylori Infection: Implications of Rising Antibiotic Resistance

Colin W. Howden, MD, William D. Chey, MD, and Nimish B. Vakil, MD

July 2014, Volume 10, Issue 7, Supplement 3 Clinical Rationale for Confirmation Testing After Treatment of Helicobacter pylori Infection: Implications of Rising Antibiotic Resistance Moderator Colin W. […]

June 2014:

Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014

Steven L. Flamm, MD

Volume 10, Issue 6, Supplement 2 The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, […]

April 2014:

The Gastro & Hep Report Spring 2014

Comprehensive Reports on the Latest Advances in Gastroenterology and Hepatology from: 2013 Advances in Inflammatory Bowel Diseases December 12-14, 2013 Hollywood, Florida 64th Annual Meeting of the […]

January 2014:

Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013

Ira M. Jacobson, MD

Volume 10, Issue 1, Supplement 1 January 2014 The 64th Annual Meeting of the American Association for the Study of Liver Diseases November 1-5, 2013 • […]

November 2013:

Clinical Roundtable Monograph: An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D

Brian E. Lacy, MD, PhD , William D. Chey, MD, and Lin Chang, MD

Volume 9, Issue 11, Supplement 5  November 2013   Clinical Roundtable Monograph: An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D Moderator Brian E. Lacy, […]

August 2013:

Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring

William J. Sandborn, MD

Volume 9, Issue 8, Supplement 4  August 2013 Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring Digestive Disease Week 2013 May 18–21, 2013 […]

June 2013:

Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013

Volume 9, Issue 6, Supplement 3 June 2013 The 48th Annual Meeting of the European Association for the Study of the Liver April 24–28, 2013 • […]

April 2013:

Extending Survival With the Use of Targeted Therapy in the Treatment of Hepatocellular Carcinoma

Robert G. Gish, MD, Richard S. Finn, MD, Jorge A. Marrero, MD, MS

Moderator Robert G. Gish, MD Chief, Section of Hepatology UC San Diego Health Systems San Diego, California Discussants Richard S. Finn, MD Associate Professor of Medicine […]

The Gastro & Hep Report: Spring 2013

Comprehensive Reports on the Latest Advances in Gastroenterology and Hepatology from: • The 2012 Annual Scientific Meeting of the American College of Gastroenterology October 19–24, 2012 […]

January 2013:

Advances in the Treatment of Hepatitis C Virus Infection From AASLD 2012

Fred Poordad, MD

Volume 9, Issue 1, Supplement 1 January 2013 Advances in the Treatment of Hepatitis C Virus Infection From AASLD 2012 The 63rd Annual Meeting of the […]

November 2012:

Clinical Roundtable Monograph: Risk of Biologic Therapy–Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn’s Disease

Gary R. Lichtenstein, MD, Stephen B. Hanauer, MD, and William J. Sandborn, MD

Abstract: For treatment of moderate-to-severe active Crohn’s disease, clinicians generally rely on immuno­suppressants (including azathioprine and 6-mercaptopurine), corticosteroids, and antibodies against tumor necrosis factor α. However, a significant proportion of patients do not respond to these therapies, lose response over time, or are intolerant to these therapies. In such cases, one of the only remaining pharmacologic treatment options is natalizumab, an α4 integrin–targeted antibody. Unfortunately, 3 cases of progressive multifocal leukoencephalopathy (PML) were reported in natalizumab-treated patients in 2005, shortly after natalizumab’s approval by the US Food and Drug Administration (FDA). Natalizumab was subsequently withdrawn from the market but was then reintroduced in 2006 under close supervision by the FDA. Careful review of postmarketing data revealed 3 major risk factors for the development of natalizumab-associated PML, the most significant of which is prior exposure to the JC virus (JCV). To help identify patients who may be at higher risk for developing natalizumab-associated PML, a JCV antibody assay was developed that can detect anti-JCV antibodies in patients’ blood. Clinicians can now consider a patient’s anti-JCV antibody status together with the other major risk factors for natalizumab-associated PML—duration of natalizumab therapy and prior immunosuppressant use—to more accurately gauge the risks and benefits of natalizumab therapy in a particular patient.

Clinical Roundtable Monograph: Contemporary Diagnostic Strategies for the Detection of Helicobacter pylori Infection

Adam B. Elfant, MD, FACG, Colin W. Howden, MD, and Neil Stollman, MD, FACP, FACG, AGAF

Helicobacter pylori infection is highly prevalent, affecting approximately half of the world’s population. While the majority of infected individuals are asymptomatic, H. pylori infection is associated with certain diseases, including peptic ulcers (either duodenal or gastric), gastritis, and 2 malignancies—gastric cancer and gastric mucosa–associated lymphoid tissue lymphoma. Many of the epidemiologic associations between these diseases and H. pylori infection have been further validated by treatment studies, which show that effective eradication therapy correlates with a decreased risk of disease. A variety of testing strategies are used to detect H. pylori infection. Serologic techniques are widely available and inexpensive, but they are no longer preferred as they have low sensitivities and specificities, and they may show a positive result for a long period following effective therapy. The remaining testing methods are divided into 2 categories: invasive tests (which require endoscopy) and noninvasive tests. Noninvasive test methods such as the urea breath test and stool antigen test have gained popularity due to their high sensitivities and specificities. Further, both of these methods may be used to confirm the absence of infection following eradication therapy. Due to the increasing incidence of treatment failure (caused in part by antibiotic resistance), post-treatment testing is recommended to confirm H. pylori eradication.

October 2012:

The Gastro & Hep Report: Fall 2012

Comprehensive Reports on the Latest Advances in Gastroenterology and Hepatology From:
• The 47th Annual Meeting of the European Association for the Study of the Liver
April 18–22, 2012 • Barcelona, Spain
• Digestive Disease Week 2012
May 19–22, 2012 • San Diego, California

September 2012:

Clinical Roundtable Monograph: Anemia Management in the Era of Triple Combination Therapy for Chronic HCV

Ira M. Jacobson, MD, Kris V. Kowdley, MD, FACP, FACG, AGAF, and Paul Y. Kwo, MD

Boceprevir or telaprevir plus ribavirin (RBV) and pegylated interferon-α (pegIFN-α) is the new standard-of-care therapy for patients who are chronically infected with genotype 1 hepatitis C virus (HCV). The addition of these protease inhibitors to the RBV/pegIFN-α combination regimen has significantly improved rates of sustained virologic response (SVR); however, the incidence of anemia has also increased significantly. Anemia can interfere with patients’ quality of life, work productivity, and treatment adherence. Severe anemia can cause morbidity and even mortality. For the management of anemia during triple combination therapy, RBV dose reduction is recommended as an initial course of action. Retrospective analyses of carefully selected patient cohorts suggest that RBV dose reduction does not reduce SVR rates. However, this observation needs to be confirmed in prospective trials with cohorts that more accurately reflect the challenging patients treated in real-world practice. Adequate doses of RBV should be maintained during triple combination therapy, as phase II trials have demonstrated that RBV is essential for attaining optimal SVR rates and preventing viral breakthrough, relapse, and emergence of resistant variants. This roundtable addresses key points related to the management of anemia in the era of triple combination therapy, including the increasing problem of anemia, strategies for anemia management, and the importance of maintaining adequate RBV exposure as part of the HCV treatment regimen.

August 2012:

Highlights in Crohn’s Disease and Ulcerative Colitis

William J. Sandborn, MD

Special Reporting on:
• Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active UC: PURSUIT-SC
• The Future of IBD Therapy: Individualized and Optimized Therapy and Novel Mechanisms
• Infliximab Concentration and Clinical Outcome in Patients with UC
• Vedolizumab Induction Therapy for UC: Results of GEMINI I, A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase III Trial
• Novel Infliximab and Antibody-to-Infliximab Assays Are Predictive of Disease Activity in Patients with CD
• Accelerated Step-Care Therapy with Early Azathioprine Versus Conventional Step-Care Therapy in CD
• PIANO: A 1,000-Patient Prospective Registry of Pregnancy Outcomes in Women with IBD Exposed to Immunomodulators and Biologic Therapy

July 2012:

Highlights in Anti–Tumor Necrosis Factor Monitoring

William J. Sandborn, MD

Special Reporting on:
• Novel Infliximab and Antibody-to-Infliximab Assays Are Predictive of Disease Activity in Patients with Crohn’s Disease
• Antibodies to Infliximab Can Either Be Persistent or Transient: A Retrospective Case-Control Study in IBD Patients Treated with Infliximab Maintenance Therapy
• Putting It Together: Drug Levels and Disease Activity to Tailor Therapy
• Infliximab Concentration and Clinical Outcome in Patients with Ulcerative Colitis

June 2012:

Case Study Monograph: Community Perspectives: Combining Serology, 
Genetics, and Inflammation Markers for the Diagnosis 
of IBD and Differentiation Between CD and UC

Douglas C. Wolf, MD, Bincy P. Abraham, MD, MS, Anita Afzali, MD, MPH, Paul D. Allegretti, DO, and Ronen Arai, MD

Diagnosis of inflammatory bowel disease (IBD) is complicated and is based on a combination of patient history and physical examination in association with laboratory, endoscopic, histologic, and radiographic investigations. Determination of the correct diagnosis is important for its implications in selecting treatment and in the timing and type of surgery that may be required. Information from testing incorporating serologic, genetic, and inflammatory markers can help to clarify the clinical picture. Measurement of biomarkers not only helps to differentiate a diagnosis of IBD versus non-IBD, it can also help to distinguish between ulcerative colitis and Crohn’s disease in difficult cases. In this monograph, 5 cases illustrate how specialized testing can provide important information that can aid in diagnosis.

Updates in the Treatment of Hepatitis C Virus Infection From EASL 2012

Jean-Pierre Bronowicki, MD, PhD

Special Reporting on:
• Safety of Telaprevir or Boceprevir in Combination with Peginterferon α/
Ribavirin in Cirrhotic Nonresponders. First Results of the French Early Access Program (ANRS CO20-CUPIC)
• SVR in Prior Peginterferon/Ribavirin (PR) Treatment Failures After 
Re-treatment with Boceprevir + PR: The PROVIDE Study Interim Results
• Futility Rules in Telaprevir Combination Treatment
• Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients: End-of-Treatment (Week 48) Interim Results
PLUS Meeting Abstract Summaries

March 2012:

The Gastro & Hep Report: Spring 2012

Comprehensive Reports on the Latest Advances in Gastroenterology and Hepatology From:

• The 76th American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course
October 28–November 2, 2011
Washington, DC

• The 62nd Annual Meeting of the American Association for the Study of Liver Diseases
November 4–8, 2011
San Francisco, California

• 2011 Advances in Inflammatory Bowel Diseases/Crohn’s & Colitis Foundation’s Clinical and Research Conference
December 1–3, 2011
Hollywood, Florida

January 2012:

Highlights in the Treatment of Hepatitis C Virus Infection From AASLD 2011

John M. Vierling, MD, FACP

Gastroenterology & Hepatology   Volume 8, Issue 1, Supplement 1  January 2012   A SPECIAL MEETING REVIEW EDITION Highlights in the Treatment of Hepatitis C Virus Infection […]

October 2011:

August 2011:

July 2011:

Clinical Roundtable Monograph: Recent Advances in Optimal Bowel Preparation

Philip S. Schoenfeld, MD, MSEd, MSc (Epi), Carol A. Burke, MD, Lawrence B. Cohen, MD, David M. Kastenberg , MD

Volume 7, Issue 7, Supplement 11 July 2011

June 2011:

New Developments in the Treatment of Hepatitis C Virus Infection from Digestive Disease Week 2011

Steven L. Flamm, MD

Volume 7, Issue 6, Supplement 10  June 2011 New Developments in the Treatment of Hepatitis C Virus Infection from Digestive Disease Week 2011 May 7–10, 2011 […]

May 2011:

Clinical Roundtable Monograph: Community Perspectives on Serologic and Genetic Testing for Crohn’s Disease

Marla C. Dubinsky, MD, Morris A. Barocas, MD, Charles J. Loewe, MD, Chandar Singaram, MD, MBA, Ronald Soltis, MD, Jeffrey A. Tuvlin, MD

Volume 7, issue 5, Supplement 8 May 2011

Clinical Roundtable Monograph: Optimizing Patient Outcomes in the Treatment of Ulcerative Colitis

Patrick G. Brady, MD, Gary R. Lichtenstein, MD, Paul J. Rutgeerts, MD, PhD, FRCP, AGAF

Volume 7, issue 5, Supplement 7 May 2011

April 2011:

Clinical Roundtable Monograph: Clinical Perspectives on Infliximab for the Treatment of Crohn’s Disease: Considerations from the SONIC Study

Gary R. Lichtenstein, MD, Asher Kornbluth, MD, Geert D’Haens, MD, PhD

Volume 7, Issue 4, Supplement 6 april 2011

Clinical Roundtable Monograph: Safety of Proton Pump Inhibitors

David A. Johnson, MD, David A. Peura, MD, Michael F. Vaezi, MD

Volume 7, Issue 4, Supplement 5 april 2011

March 2011:

February 2011:

Progress in the Diagnosis and Treatment of Inflammatory Bowel Disease

Edward V. Loftus, Jr., MD

Volume 7, Issue 2, Supplement 3  February 2011

January 2011:

December 2010:

October 2010:

September 2010:

Integrating Recent Data in Managing Adverse Events in the Treatment of Hepatocellular Carcinoma

Robert G. Gish, MD, Ghassan K. Abou-Alfa, MD, Myron J. Tong , MD, PhD

An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium

Lin Chang, MD, Brian E. Lacy, PhD, MD, Brennan M. R. Spiegel, MD, MSHS

August 2010:

July 2010:

June 2010:

Treatment of Patients With Diabetic Gastroparesis

Henry P. Parkman, MD, Ronnie Fass, MD, Amy E. Foxx-Orenstein, DO

April 2010:

The Treatment of Hepatic Encephalopathy in the Cirrhotic Patient

Arun J. Sanyal, MD, Kevin D. Mullen, MD, Nathan M. Bass, MD, PhD

March 2010:

A Multidisciplinary Approach to the Management of Hepatocellular Carcinoma

Robert G. Gish, MD, Jorge A. Marrero, MD, MS, Al B. Benson III, MD

Treatment Options for HCV Nonresponders and Relapse Patients

Brian L. Pearlman, MD, FACP, Maria H. Sjogren, MD, MPH, FACP

February 2010:

January 2010:

December 2009:

The ACG Evidence-Based Review on the Management of Irritable Bowel Syndrome: Recommendations from Bench to Bedside

William D. Chey, MD, Jennifer A. Christie, MD, Mark Pimentel, MD, FRCP(C)

November 2009:

Current Issues in Optimal Bowel Preparation

Lawrence B. Cohen, MD, David M. Kastenberg, MD, David B. Mount, MD, Alan V. Safdi, MD

October 2009:

August 2009:

Emerging Issues in Gastroenterology and Hepatology

Nathan M. Bass, MD, PhD, Brian Feagan, MD

July 2009:

Therapeutic Targets for Emerging Biologic Therapies in IBD

Stephen B. Hanauer, MD, Scott E. Plevy, MD, Bruce E. Sands, MD, MS, Stephan R. Targan, MD

June 2009:

May 2009:

April 2009:

Patient Selection and Treatment Strategies for H. pylori Eradication

M. Brian Fennerty, MD, William D. Chey, MD, Nimish Vakil, MD

Challenging Cases in the Management of Hepatitis C Viral Infection

Brian Pearlman, MD, FACP, Kenneth D. Rothstein, MD, Atif Zaman, MD, MPH, Kenneth Ingram, PA-C

March 2009:

Evolving Strategies in Hepatocellular Carcinoma Screening and Treatment: A Discussion Post-AASLD 2008

Hashem B. El-Serag , MD, MPH, Robert G. Gish, MD, Jorge A. Marrero, MD, MS

Ribavirin as a Key Factor in the Treatment of Hepatitis C

John G. McHutchison, MD, Sammy Saab, MD, MPH, Tuesdae R. Stainbrook, DO, MPH

February 2009:

Getting More From New 5-ASA Therapies: Will Better Science Lead to Better Patient Adherence?

Gary R. Lichtenstein, MD, Russell D. Cohen, MD, William J. Sandborn, MD

The Evolving Role of Serologic Markers in the Management of Pediatric IBD

Carmen Cuffari, MD, Marla Dubinsky, MD, Ernest Seidman, MDCM, FRCPC, FACG

Managing Cirrhosis: New Data on Liver Disease Complications

Ghassan K. Abou-Alfa, MD, Guy W. Neff, MD, MBA

January 2009:

Cases in Point: Risk Factors, Surveillance Strategies and Treatment Options for HCC

Robert G. Gish, MD, Al B. Benson III, MD, Morris Sherman, MB BCh, PhD, FRCP(C), Barbara Sigler Morgan, MSN, NP

Diagnostic Challenges in the Management of Irritable Bowel Syndrome

Jamie S. Barkin, MD, MACG, MACP, AGAF, FASGE, Eugene J. Burbige, MD, FACG, William D. Chey, MD, AGAF, FACG, FACP, Brian E. Lacy, MD, PhD, Nisa Kubiliun, MD, Hendrikus S. Vanderveldt, MD, MBA

December 2008:

November 2008:

5-ASA Treatment for Ulcerative Colitis: What’s on the Horizon?

Russell D. Cohen, MD, FACG, AGAF, Gary R. Lichtenstein, MD, Alan V. Safdi, MD, William J. Sandborn, MD

October 2008:

Emerging Diagnostic and Treatment Strategies for Irritable Bowel Syndrome

Lin Chang, MD, AGAF, Brian E. Lacy, PhD, MD, FACG, Eamonn M.M. Quigley, MD, FACG, Philip S. Schoenfeld, MD, MSEd, MSc (Epi), FACG

The Future Use of Interferon in the Treatment of Hepatitis C: New Formulations, New Combinations

Ira M. Jacobson, MD, John G. McHutchison, MD, Mark Sulkowski, MD

Treatment Guidelines and Clinical Practice: Optimizing Foundational Therapies for Ulcerative Colitis

Stephen B. Hanauer, MD, David T. Rubin, MD, William J. Sandborn, MD

September 2008:

The Role of Consensus Interferon in the Current Treatment of Chronic Hepatitis C Viral Infection

Eleanor N. Fish, PhD, Stephen A. Harrison, MD, Tarek Hassanein, MD

July 2008:

Updates from the Front Lines of Crohn’s Disease: Achieving a Balance Between Safety and Efficacy

William J. Sandborn, MD, Maria T. Abreu, MD, David W. Brandes, MS, MD, Remo Panaccione, MD

April 2008:

March 2008:

February 2008:

Hepatitis B Makeover: An Expert Panel Discussion

Eugene R. Schiff, MD, Nezam H. Afdhal, MD, Robert S. Brown, Jr., MD, MPH, Ira M. Jacobson, MD, F. Fred Poordad, MD

January 2008:

Improving HBV Treatment: Early Screening and Sustained Control for Improved Outcomes

Ira M. Jacobson, MD, Robert G. Gish, MD, Paul J. Pockros, MD

Discontinued Products, Uncertain Data, Changing Options: Selecting Effective and Reliable Treatment for IBS

William D. Chey, MD, Anthony J. Lembo, MD, Mark Pimentel, MD, FRCP(C), Philip Schoenfeld, MD, MSEd, Msc

View More Supplements
Millennium Medical Publishing, Inc